- Home
- VNET vs ADPT Comparison
VNET vs ADPT Comparison
Compare VNET & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNET
- ADPT
- Stock Information
- Founded
- VNET 1999
- ADPT 2009
- Country
- VNET China
- ADPT United States
- Employees
- VNET N/A
- ADPT N/A
- Industry
- VNET Computer Software: Programming Data Processing
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VNET Technology
- ADPT Health Care
- Exchange
- VNET Nasdaq
- ADPT Nasdaq
- Market Cap
- VNET 1.7B
- ADPT 1.8B
- IPO Year
- VNET 2011
- ADPT 2019
- Fundamental
- Price
- VNET $7.95
- ADPT $11.82
- Analyst Decision
- VNET Strong Buy
- ADPT Strong Buy
- Analyst Count
- VNET 3
- ADPT 7
- Target Price
- VNET $10.73
- ADPT $10.57
- AVG Volume (30 Days)
- VNET 6.9M
- ADPT 2.5M
- Earning Date
- VNET 08-26-2025
- ADPT 07-31-2025
- Dividend Yield
- VNET N/A
- ADPT N/A
- EPS Growth
- VNET N/A
- ADPT N/A
- EPS
- VNET N/A
- ADPT N/A
- Revenue
- VNET $1,186,131,469.00
- ADPT $189,527,000.00
- Revenue This Year
- VNET $15.44
- ADPT $24.46
- Revenue Next Year
- VNET $19.86
- ADPT $20.25
- P/E Ratio
- VNET $132.01
- ADPT N/A
- Revenue Growth
- VNET 14.68
- ADPT 8.61
- 52 Week Low
- VNET $1.71
- ADPT $3.51
- 52 Week High
- VNET $16.13
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- VNET 65.91
- ADPT 63.35
- Support Level
- VNET $6.82
- ADPT $11.41
- Resistance Level
- VNET $7.76
- ADPT $12.36
- Average True Range (ATR)
- VNET 0.51
- ADPT 0.59
- MACD
- VNET 0.14
- ADPT -0.01
- Stochastic Oscillator
- VNET 98.14
- ADPT 72.65
About VNET VNET Group Inc.
VNET started as AsiaCloud in 1999 and moved to the data center business with its first self-developed data center opening in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of June 2024, it had 48,516 self-built retail cabinets with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 358 MW of wholesale capacity in service with a further 297 MW under construction and a further 489 MW held for future development.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).